US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 7541513B2
· Bruggemann et al.
· 2009
[cited by applicant]
US 8367888B2
· Bruggemann et al.
· 2013
[cited by applicant]
US 8883150B2
· Craig et al.
· 2014
[cited by applicant]
US 9034324B2
· Kalled et al.
· 2015
[cited by applicant]
US 9365655B2
· Craig et al.
· 2016
[cited by applicant]
US 20010024811A1
· Khosla et al.
· 2001
[cited by applicant]
US 20060008548A1
· Tung
· 2006
[cited by applicant]
US 20100122358A1
· Bruggemann et al.
· 2010
[cited by applicant]
US 20160355591A1
· Goldenberg et al.
· 2016
[cited by applicant]
US 20200085839A1
· Sidransky et al.
· 2020
[cited by applicant]
US 20200339685A1
· Schellenberger et al.
· 2020
[cited by applicant]
US 20230082151A1
· Trinklein et al.
· 2023
[cited by applicant]
US 20230272075A1
· Trinklein et al.
· 2023
[cited by applicant]
WO 1996027011
· 1993
[cited by applicant]
WO 1996032478
· 1996
[cited by applicant]
WO 1997034631
· 1997
[cited by applicant]
WO 2001024811
· 2001
[cited by applicant]
WO 2001024812
· 2001
[cited by applicant]
WO 2002066516
· 2002
[cited by applicant]
WO 2006008548
· 2006
[cited by applicant]
WO 2016048938
· 2016
[cited by applicant]
WO 2017223111
· 2017
[cited by applicant]
WO 2018052503
· 2018
[cited by applicant]
WO 2018237037
· 2018
[cited by applicant]
WO 2019006072
· 2019
[cited by applicant]
WO 2020018922
· 2020
[cited by applicant]
Wang et al., “A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture,” (2018) mAbs 10:8, 1226-1235.
[cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” (1996) Protein Eng. 9(7):617-621.
[cited by applicant]
Gupta et al., “Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health,” (2019) Journal of Interferon & Cytokine Research 40(1):19-23.
[cited by applicant]
Crescioli et al., “lgG4 Characteristics and Functions in Cancer Immunity,” (2016) Curr Allergy Asthma Rep 16:7.
[cited by applicant]
Labrijn et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo,” (2009) Nature Biotechnology 27:767-71.
[cited by applicant]
Muyldermans, “Single domain camel antibodies: current status,” 2001; Journal of Biotechnology 74(4):277-302.
[cited by applicant]
Revets et al., “Nanobodies as Novel Agents for Cancer Therapy,” (2005) Expert Opinion Biological Therapy 5(1):111-124.
[cited by applicant]
Nuttall et al., “Isolation and Characterization of an IgNAR Variable Domain Specific for the Human Mitochondrial Translocase Receptor Tom70,” (2003) Eur. J. Biochem. 270:3543-3554.
[cited by applicant]
Nuttall et al., “Selection and Affinity Maturation of IgNAR Variable Domains Targeting Plasmodium falciparum AMA1,” (2004) Proteins; Structure, Function and Bioinformatics 55:187-197.
[cited by applicant]
Dooley et al., “Selection and Characterization of Naturally Occuring Single-domain (IgNAR) Antibody Fragments from Immunized Sharks by Phage Display,” (2003) Molecular Immunology 40:25-33.
[cited by applicant]
Jaton et al., “Recovery of Antibody Activity Upon Reoxidation of Completely Reduced Polyalanyl Heavy Chain and its Fd Fragment Derived from Anti-2,4-dinitrophenyl Antibody,” (1968) Biochemistry 7(12):4185-4195.
[cited by applicant]
Sitia et al., “Developmental Regulation of IgM Secretion: The Role of the Carbosy-terminal Cysteine,” (1990) Cell, 60:781-790.
[cited by applicant]
Van der Linden et al., “Comparison of Physical Chemical Properties of Llama VHH Antibody Fragments and Mouse Monoclonal Antibodies,” (1999) Biochimica et Biophysica Acta 1431:37-46.
[cited by applicant]
Frenken et al., “Isolation of Antigen Specific Llama V
[cited by applicant]
Ghahroudi et al., “Selection and Identification of Single Domain Antibody Fragments from Camel Heavy-chain Antibodies,” (1997) FEBS Letters 414:521-526.
[cited by applicant]
Nguyen et al., “Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells,” (2003) Immunology; 109(1):93-101.
[cited by applicant]
Bruggemann et al., “Heavy-Chain-Only Antibody Expression and B-Cell Development in the Mouse,” (2006) Crit. Rev. Immunol. 26(5):377-90.
[cited by applicant]
Zou et al., “Heavy Chain-Only Antibodies are Spontaneously Produced in Light Chain-Deficient,” (2007) J Exp Med 204(13):3271-3283.
[cited by applicant]
Geurts et al., “Knockout Rats via Embryo Microinjection of Zinc-finger Nucleases,” (2009) Science 325(5939):433.
[cited by applicant]
Iri-Sofla et al., “Nanobody-based Chimeric Receptor Gene Integration in Jurkat Cells Mediated by PhiC31 Integrase,” (2011) Experimental Cell Research 317:2630-2641.
[cited by applicant]
Jamnani et al., “T Cells Expressing VHH-directed Oligoclonal Chimeric HER2 Antigen Receptors: Towards Tumor-directed Oligoclonal T Cell Therapy,” (2014) Biochimica et Biophysica Acta 1840:378-386.
[cited by applicant]
Gras et al., “BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes,” (1995) International Immunology 7(7):1093-1106.
[cited by applicant]
Tai et al., “Novel Anti-B-Cell Maturation Antigen Antibody-drug Conjugate (GSK2857916) Selectively Induces Killing of Multiple Myeloma,” (2014) Blood 123(20): 3128-38.
[cited by applicant]
Ali et al., “T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma,” (2016) Blood 128(13):1688-700.
[cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” (1975) Nature 256:495-497.
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” (1987) Journal of Molecular Biology 196(4):901-917.
[cited by applicant]
Lefranc et al., “IMGT, the international ImMunoGeneTics database,” (1999) Nucleic Acids Research, 27(1):209-212.
[cited by applicant]
Zhao et al., “A germline knowledge based computational approach for determining antibody complementarity determining regions,” (2010) Molecular Immunology 47(4):694-700.
[cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” (1989) Nature 342:877-883.
[cited by applicant]
Honegger, “Yet Another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” (2001) Journal of Molecular Biology 309(3):657-670.
[cited by applicant]
Ofran et al. “Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B-cell epitopes,” (2008) Journal of Immunology 181(9):6230-6235.
[cited by applicant]
Almagro “Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires,” (2004) Journal of Mo…
[cited by applicant]
Padlan et al., “Identification of specificity-determining residues in antibodies,” (1995) FASEB Journal 9(1):133-139.
[cited by applicant]
Roux et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” (1998) Journal of Immunology 161(8):4083-4090.
[cited by applicant]
Lund et al., “Expression and characterization of truncated forms of humanized L243 IgG1,” (2000) European Journal of Biochemistry 267(24):7246-7256.
[cited by applicant]
Boesch et al., “Highly parallel characterization of IgG Fc binding interactions,” (2014) MAbs 6(4):915-927.
[cited by applicant]
Chen et al., “Fusion protein linkers: Property, design and functionality ,” (2013) Advanced Drug Delivery Reviews 65(10): 1357-1369.
[cited by applicant]
Hamers-Casterman et al., “Naturally Occurring Antibodies Devoid of Light Chains,” (1993) Letters to Nature 363:446-448.
[cited by applicant]
Desmyter et al., “Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody,” (2001) Journal of Biological Chemistry 276(28):26285-26290.
[cited by applicant]
Jackson et al., “Driving CAR T-cells Forward,” (2016) Nature Reviews Clinical Oncology 13:370-383.
[cited by applicant]
Ravetch et al., “Fc Receptors,” (1991) Annual Review of Immunology 9:457-492.
[cited by applicant]
Clynes et al., “Fc Receptors are Required in Passie and Active Immunity to Melanoma,” (1998) PNAS (USA) 95(2):652-656.
[cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” (1996) Journal of Immunological Methods 202(2):163-171.
[cited by applicant]
Concepcion et al., “Label-Free Detection of Biomolecular Interactions Using BioLayer Interferometry for Kinetic Characterization,” (2009) Combinatorial Chemistry & High Throughput Screening 12(8):791-800.
[cited by applicant]
Menoret et al., “Characterization of Immunoglobulin Heavy Chain Knockout Rats,” (2010) European Journal Immunology 40:2932-2941.
[cited by applicant]
Cui et al., “Targeted Integration in Rat and Mouse Embryos with Zinc-finger Nucleases,” (2011) Nature Biotechnology 29(1):64-67.
[cited by applicant]
Carpenter et al., “B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma,” (2013) Clinical Cancer Research 19(8):2048-2060.
[cited by applicant]
Tai et al., “APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment,” (2016) Blood 127(25):3225-3236.
[cited by applicant]
Sanz et al., “B Cells as Therapeutic Targets in SLE,” (2010) Nature Reviews Rheumatology 6:326-337.
[cited by applicant]
Dai et al., “Chimeric Antigen Receptors Modified T-cells for Cancer Therapy,” (2016) J Natl Cancer Inst 108(7):dvj439.
[cited by applicant]
Omniab, “Naturally Optimized Human Antibodies,” (Feb. 23, 2016) retrieved from Internet: URL:http://content.stockpr.com/omniab/db/252/746/file/OmniAb.pdf.
[cited by applicant]
Armitage, “A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma,” (1997) Blood 89(11):3909-3918.
[cited by applicant]
Hanes et al., “New advances in microsphere-based single-dose vaccines,” (1997) Advanced Drug Delivery Reviews 28(1):97-119.
[cited by applicant]
Langer, “New Methods of Drug Delivery,” (1990) Science 249(4976):1527-1533.
[cited by applicant]
Banihashemi et al., “Development of Specific Nanobodies (VHH) for CD19 Immuno-targeting of Human B-lymphocytes,” (2018) Iranian Journal of Basic Medical Sciences 21(5):455-464.
[cited by applicant]
Malik et al., “A Novel Fully Human Bispecific CD19 x CD3 Antibody that Kills Lymphoma Cells with Minimal Cytokine Secretion,” (2018) 132(1):1671.
[cited by applicant]
Naddafi et al., “Anti-CD19 Monoclonal Antibodies: A New Approach to Lymphoma Therapy,” (2015) IJMCM 4(3):143-151.
[cited by applicant]
Sadelain et al., “CD19 Car T Cells,” (2017) Cell 171:1471.
[cited by applicant]
Miller et al., “Design, Construction, and In Vitro Analyses of Multivalent Antibodies,” (2003) Jour. of Immunology 170(9):4854-4861.
[cited by applicant]
Duncan et al., “Localization of the binding site for the human high-affinity Fc receptor on IgG ,” (1988) Nature 332:563-564.
[cited by applicant]
Tao et al., “Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation,” (1993) Journal of Experimental Medicine 178(2):661-667.
[cited by applicant]
Canfield et al.“ The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region,” J. Exp. Med. 173:1483-1491, (1991) J. E…
[cited by applicant]
Armour et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,” (1999) Eur J Immunol. 29(8):2613-2624.
[cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,” (2001) J Biol Chem. 276(9):6591-6604.
[cited by applicant]